TrialCurvePEONY: reconstructed Kaplan–Meier curves
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Nat Commun. 2024 Mar 9;15:2153. doi: 10.1038/s41467-024-45591-7 |
|---|---|
| DOI | 10.1038/s41467-024-45591-7 |
| Registry | NCT02586025 |
| Phase | Phase 3 |
| Conditions | Breast Cancer |
| Interventions | FEC Chemotherapy, Surgery, Docetaxel, Pertuzumab, Placebo, Trastuzumab |
| Sponsor | Hoffmann-La Roche |
| Enrolment | 329 |
| Source licence | Figure published under CC BY 4.0 |
Event-free survival (EFS) — ITT population
From figure panel a · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Pertuzumab arm not reached; Placebo arm not reached. Survival at 2 years: Pertuzumab arm 91%; Placebo arm 85%. Hazard ratio Pertuzumab arm vs Placebo arm 0.55 (95% CI 0.33–0.92).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Pertuzumab arm | 219 | 32 | not reached |
| Placebo arm | 110 | 27 | not reached |
- Pertuzumab arm vs Placebo arm: reconstructed HR 0.55 (95% CI 0.33–0.92)
Landmark survival (reconstructed)
| Time | Pertuzumab arm | Placebo arm |
|---|---|---|
| 1 yr | 98.1% | 92.3% |
| 2 yr | 90.8% | 85.4% |
| 3 yr | 89.3% | 80.4% |
| 5 yr | 85.3% | 73.4% |
Checks against the published figure
- Pertuzumab arm events: printed 32, reconstructed 32 pass
- Pertuzumab arm n: printed 219, reconstructed 219 pass
- Placebo arm events: printed 27, reconstructed 27 pass
- Placebo arm n: printed 110, reconstructed 110 pass
- hazard ratio (direction inferred): printed 0.53, reconstructed 0.55 pass
Disease-free survival (DFS) — All patients who underwent surgery
From figure panel b · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Pertuzumab arm not reached; Placebo arm not reached. Survival at 2 years: Pertuzumab arm 92%; Placebo arm 87%. Hazard ratio Pertuzumab arm vs Placebo arm 0.54 (95% CI 0.31–0.92).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Pertuzumab arm | 210 | 29 | not reached |
| Placebo arm | 105 | 25 | not reached |
- Pertuzumab arm vs Placebo arm: reconstructed HR 0.54 (95% CI 0.31–0.92)
Landmark survival (reconstructed)
| Time | Pertuzumab arm | Placebo arm |
|---|---|---|
| 1 yr | 98.0% | 92.0% |
| 2 yr | 91.6% | 87.0% |
| 3 yr | 90.0% | 80.9% |
| 5 yr | 86.4% | 74.8% |
Checks against the published figure
- Pertuzumab arm events: printed 29, reconstructed 29 pass
- Pertuzumab arm n: printed 210, reconstructed 210 pass
- Placebo arm events: printed 25, reconstructed 25 pass
- Placebo arm n: printed 105, reconstructed 105 pass
- hazard ratio (direction inferred): printed 0.52, reconstructed 0.536 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- PATHWAY: Overall survival; Progression-free survival by blinded independent central review; Progres
- PANTHER: Breast cancer recurrence-free survival events (cumulative incidence)
- ACE-Breast-02: Overall survival; Progression-free survival assessed by BICR; Progression-free survival as
- Culmerciclib + fulvestrant in HR+/HER2− breast cancer: Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials